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Abstract 
Purpose: Breast-conserving treatment (BCT) have emerged as an alternative to mastectomy in patients with ipsi-
lateral breast tumor recurrence (IBTR). We evaluated survival outcomes and treatment-related toxicity in a series of 
40 patients with IBTR, who underwent tumorectomy plus interstitial brachytherapy (APBI) as a salvage treatment.
Material and methods: Retrospective analysis included 40 patients diagnosed with IBTR and treated with intra-
operative (26 patients) or post-operative (14 patients) multicatheter brachytherapy for APBI at our institution between 
June 2002 and October 2017. We assessed cosmesis, toxicity, overall survival (OS), and cancer-specific survival (CSS).
Results: Tumorectomy was performed in all cases, including intraoperative tumor margin assessment and sentinel 
node biopsy. Median age was 65 years (range, 41-92). The total prescribed dose was 32 Gy (8 fractions) in 19 patients 
and 34 Gy (10 fractions) in 20 patients. One elderly patient (age 92) received a single fraction of 16 Gy. Median fol-
low-up was 61.5 months (range, 6-153). A median of 14 tubes were inserted. Mean treated V100 was 115 cc. Two patients 
developed a second relapse at 3 and 5 years after salvage treatment: one patient underwent salvage mastectomy and 
remains alive 10 years after brachytherapy, and the second one developed both local relapse and bone metastasis. The 
disease is stable at present. Five-year OS and CSS rates were 85.3% and 97.5%, respectively. Two patients died from 
cancer-related causes. Acute and late toxicity rates were low; seven patients developed acute infectious mastitis. Late 
fibrosis > grade 3 and late mastitis were observed in 14 and 6 cases, respectively. 
Conclusions: Second BCT with APBI as a salvage treatment in ipsilateral breast recurrence achieves good local dis-
ease control, with a satisfactory toxicity profile compared to mastectomy. This approach seems to be safe and effective, 
although more data from randomized trials are needed. 
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Purpose 
Local ipsilateral breast tumor recurrences (IBTR) are 
relatively uncommon and highly heterogeneous. The risk 
of IBTR depends on numerous factors, including age, in-
herited susceptibility, tumor characteristics, type of pri-
mary cancer treatment, and lifestyle factors such as obe-
sity and alcohol use. Recurrence rates are approximately 
10% at 10 years and 20% at 15 years [1]. Several studies 
[2,3] have sought to identify prognostic factors for recur-
rent disease after radical treatment for invasive breast 
cancer. Those studies have found that outcomes are worse 
in patients who experience a recurrence within two years 
from the initial treatment compared to those with a longer 
recurrence-free interval. This difference may, at least par-
tially, be explained by the hypothesis that early recurrenc-
es are caused by cell repopulation due to persistent micro-
scopic disease, whereas late recurrences are more likely 
attributable to be due to a new primary tumor formation. 
In recurrent disease, salvage radiotherapy is generally 
not an option, because most patients who develop locally 
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recurrent disease have previously undergone breast ir-
radiation. As a result, until lately, the standard salvage 
treatment in these cases was mastectomy. However, in 
recent years, several single-institution studies [4] have 
investigated the use of breast-conserving surgery (BCS) 
with or without adjuvant radiotherapy. A literature re-
view conducted by Hannoun-Levi et al. showed that pa-
tients treated with a second breast-conserving treatment 
(BCT), that is tumorectomy plus radiotherapy, had only 
a 10% risk of developing another recurrence at the same 
site, a rate that is comparable to the recurrence rate ob-
served in patients treated with salvage mastectomy. In 
both groups, overall survival (OS) was the same (75% at 
10 years) [4]. In addition, a multicentric trial conducted 
by the GEC-ESTRO Breast Cancer Working Group found 
that patients who underwent salvage therapy involving 
lumpectomy plus re-irradiation by interstitial multicath-
eter brachytherapy, had a recurrence rate for a second 
IBTR of approximately 5% [5]. These data suggest that 
combining BCS with local irradiation may be an emerg-
ing standard of care in IBTR, especially when the aim is to 
preserve the breast. This combined approach is support-
ed by data from several retrospective studies [6], but no 
randomized trials have yet been performed to determine 
non-inferiority. In this context, more data to support the 
safety and efficacy of this approach would be desirable. 
The most common approach for re-irradiation in pa-
tients undergoing a second BCT is interstitial brachyther-
apy, either low-dose-rate (LDR) or high-dose-rate (HDR) 
[7,8,9,10,11,12]. However, external beam radiation thera-
py (EBRT) and intraoperative radiation therapy (IORT) 
(50 kV photons) have also been described [13,14]. 
The aim of the present retrospective study was to 
evaluate the outcomes and treatment-related toxicity 
in a series of patients who underwent intraoperative or 
post-operative multicatheter interstitial brachytherapy 
for locally recurrent breast cancer. 
Material and methods 
Between June 2002 and October 2017, 40 patients un-
derwent BCT at our institution (the Catalan Institute of 
Oncology, Barcelona, Spain) to treat an IBTR. The treat-
ment consisted of a second tumorectomy plus either in-
traoperative (n = 26) or post-operative (n = 14) multicath-
eter brachytherapy implant for accelerated partial breast 
irradiation (APBI). We retrospectively analyzed overall 
survival, toxicity, and cosmesis. The main characteristics 
of the primary tumor are summarized in Table 1. In all 
cases, the treatment included tumorectomy, with a re-
section margin that included sufficient normal breast tis-
sue to ensure clear margins. Sentinel node biopsy (SNB) 
was performed in all cases, except for patients who had 
already undergone axillary lymph node dissection for 
a primary tumor. 
Eligibility criteria for multicatheter brachytherapy 
were as follows: 1) Locally recurrent disease; 2) Breast 
anatomy suitable for multicatheter implantation; 3) Re-
fusal to undergo mastectomy after previous treatment 
with BCS and adjuvant whole-breast irradiation (WBI); 
and 4) Unicentric, unifocal tumor with negative mar-
gins and negative SNB. Follow-up consisted of a com-
plete clinical examination and was performed during 
post-operative stage at first or second month, then every 
6 months for the first two years, and annually thereafter. 
All the patients underwent an annual mammography. 
This study was conducted in accordance with our in-
stitutional protocols, and all of the cases were presented 
Table 1. Primary tumor characteristics 
Characteristics n (%) 
Histological subtype 
Ductal invasive 25 (62.5) 
Unknown 9 (22.5) 
Others 6 (15) 
T stage 
pTis 4 (10) 
pT1 15 (37.5) 
pT2 6 (15) 
pT3 1 (2.5) 
Unknown 14 (35) 
N stage 
cN0 (sn) 18 (45) 
pN1 6 (15) 
pN2 2 (5) 
Unknown 14 (35) 
Molecular subtype 
Luminal A 10 (25) 
Luminal B 2 (5) 
Triple negative 1 (2.5) 
Unknown 27 (67.5) 
Systemic treatment 
Chemotherapy 10 (25) 
Hormonotherapy 16 (40) 
Previous radiotherapy treatment 
50 Gy + BQ boost 35 (87.8) 
50 Gy + EBRT boost 3 (7.5) 
Unknown 2 (5) 
Late toxicity 
G0-G1 28 
G2 3 
G3 0 
Unknown 9 
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at a breast cancer tumor board. Written informed consent 
was obtained from every patient prior to treatment. 
Implant technique and treatment delivery 
All patients underwent tumorectomy. During the sur-
gical procedure, six metallic clips were inserted around 
the tumor bed margins following the technique described 
by Major et al. [15]. Multicatheter implantation was per-
formed intraoperatively in 26 patients and post-operative-
ly in 14 patients. Intraoperative implantation is presented 
in Figure 1. After tumorectomy, tissue samples from the 
sentinel lymph node and tumor margins were sent for in-
traoperative pathological evaluation. After the patholog-
ical report confirmed a negative result, we proceeded to 
manually insert metallic needles into the open cavity fol-
lowing the technique described by our group previously 
[16]. Post-operative implantation is presented in Figure 2. 
In the 14 patients who underwent post-operative 
brachytherapy, this procedure was performed from 15-45 
days after tumorectomy under direct visualization of the 
seroma using ultrasound guidance. In all cases, a plastic 
guide template with needle holes was used to achieve 
geometric distribution. The needles were spaced to form 
equilateral triangles of 1.6 cm and inserted in two to four 
planes. After insertion, the needles were replaced with 
plastic tubes. The number of applicators and tubes varied 
on a case by case basis according to the size of the tu-
mor cavity and individual breast anatomy. Next, a com-
puted tomography (CT) scan with 2 mm slice thickness 
was performed. The Oncentra system (Elekta Company; 
Veenendaal, the Netherlands) was used to define the 
planning target volume (PTV), including a 2 cm margin 
of safety to the tumor edge [15]. In cases in which the PTV 
overlapped the skin and/or chest wall, a 5 mm margin 
was cropped out of these structures [17]. A modified 
Paris system was used for dosimetric purposes [18]. The 
treatment planning parameters were as follows: ≥ 90% of 
the defined PTV had to receive 100% of the prescribed 
dose (coverage ratio ≥ 0.9); maximum dose to the skin: 
Fig. 1. Intraoperative implantation: A) Manual insertion of metallic needles into the open cavity; B) Needles inserted in the 
inferior plane and sutured skin 
Fig. 2. Post-operative implantation: A) The needles were spaced to form equilateral triangles of 1.6 cm using a plastic template; 
B) Direct visualization of the seroma using ultrasound guidance 
B
B
A
A
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≤ 70% of the prescribed dose; D90 > 100%; V150 < 50%, 
with a dose non-uniformity ratio (DNR) < 0.35. 
Until September 2012, we used the treatment scheme 
(3.4 Gy/10 fractions) described by Vicini et al. [19]. How-
ever, this treatment scheme was changed in October 2012, 
as our center participated in the GEC-ESTRO randomized 
trial [20]. Accordingly, the patients in this study received 
either 10 fractions of 3.4 Gy (n = 20) or 8 fractions of 
4 Gy (n = 19). One elderly patient (age 92) received a sin-
gle 16 Gy fraction due to her advanced age and poor per-
formance status [21,22]. Notwithstanding these differenc-
es in fractionation schedules, the equivalent total dose in 
2 Gy fractions (EQD2), with a tumor α/β ratio value of 
4 was similar in both schemes (41.93 Gy and 42.67 Gy, 
respectively), as were the biologically-effective doses 
(BEDs): 62.9 Gy and 64 Gy, respectively. The EQD2 for 
a single fraction of 16 Gy is equal to 53 Gy [23,24]. 
Results 
A total of 40 women diagnosed with IBTR under-
went salvage HDR brachytherapy after BCS. Of these 
40 patients, 26 (65%) underwent intraoperative interstitial 
multicatheter implant, while the other 14 patients (35%) 
received a post-operative implant. Median follow-up was 
61.5 months (range, 12-153). Median age at recurrence 
was 65 years (range, 41-92). Most patients (25/40, 62.5%) 
were ≥ 60 years. The demographic and tumor character-
istics are provided in Table 2. The median time to local 
recurrence (LR) was 10 years (range, 2-29). In one patient, 
the recurrence-free interval was 29 years; in that case, the 
recurrence was located at the edge of the primary surgi-
cal bed and was interpreted as a late relapse rather than 
as a new primary cancer in the same quadrant. Most 
patients (n = 26, 65%) had infiltrating ductal carcinoma 
(Table 2), and 70% had luminal A disease. A median of 
14 tubes (range, 7-18) were inserted. In almost all cases 
(70%), 3 catheter planes were used. Nineteen patients 
(47.5%) were treated according to the revised GEC-ES-
TRO treatment schedule (32 Gy in 8 fractions), 20 patients 
(50%) were treated with the classic schedule (34 Gy in 
10 fractions), and one patient received 16 Gy in a sin-
gle faction. The mean V100 was 115 cc, with a median of 
132.5 cc (range, 54.8-164 cc). Mean V150 was 38.5 cc (range, 
16-65 cc). Treatment characteristics and parameters of 
the dosimetric analysis are provided in Table 3. At least 
90% of the defined PTV received 100% of the prescribed 
dose (coverage index > 0.9). Underdosing of the PTV was 
accepted only to meet dose constraints for the skin and 
chest wall. Mean coverage index was 90.1% (median, 
92.25%, min 78.61, max 99%). 
Disease control 
In our series, two patients developed a second relapse 
at 3 and 5 years after salvage treatment, respectively. One 
patient underwent salvage mastectomy and remains free 
of disease and alive 10 years after brachytherapy. The sec-
ond one developed both local relapse and bone metasta-
sis. She was treated with systemic therapy; the disease is 
stable at present. Overall survival at 3 and 5 years were 
97% and 85.3%, respectively. Five-year CSS was 96%. The 
rate of local relapse (local relapse-free survival), evalu-
ated with Kaplan-Meier analysis was 96.6% at 5 years 
and 91.7% at 7 years. Three patients developed distant 
metastasis: one at 1 month, second at 3 years, and third 
patient at 10 years. Five-year metastasis-free survival at 
3 and 5 years was 94% (±8%). There were two cancer- 
related deaths, which was due to metastatic disease 4 and 
10 years after salvage treatment. Bone and lymph node 
metastases were detected in one patient 30 days after sal-
vage treatment, a finding that suggests the patient had 
been understated at the initial surgery. At the time of 
Table 2. Patient demographics and characteri-
stics of recurrent tumor 
Parameter n (%) 
Follow-up (months)
Median 61.5 
Range 6-153 
Time between primary cancer and recurrence (years)
Median 10.5 
Range 2-29 
Age (years) 
Median 65 
Range 41-92 
41-59 14 (35) 
60-69 11 (27.5) 
> 70 15 (37.5) 
Histological subtype 
Ductal invasive 26 (65) 
Carcinoma in situ 8 (20) 
Mucinous invasive 2 (5) 
Papillary invasive 3 (7.5) 
Lobular invasive 1 (2.5) 
Intrinsic subtype 
Luminal A 28 (70) 
Luminal B 8 (20) 
ErB2 overexpression 3 (7.5) 
“Basal Like” 1 (2.5) 
Grading 
1 9 (22.5) 
2 13 (32.5) 
3 11 (27.5) 
Unknown 7 (17.5) 
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writing the paper, this patient remains alive, currently 
undergoing chemotherapy. A total of 3 patients (7.5%) 
died of causes unrelated to cancer. No evidence of relapse 
was observed in most cases (34/40 patients, 85%). 
Toxicity and cosmetic outcomes 
One patient developed a G2 hematoma. Acute infec-
tious mastitis was observed in 7 patients (17.5%). Due to 
this relatively high infection rate, prophylactic antibiot-
ics are now routinely administered at our institution for 
all intraoperative approaches. None of the patients who 
underwent post-operative catheter implantation devel-
oped an infection, even without the use of prophylac-
tic antibiotics. Grade (G) 0-2 late fibrosis was observed 
in 65% of the patients, while 27.5% (n = 11) and 7.5% 
(n = 3) developed G3 and G4 late fibrosis, respectively. 
At the last follow-up visit, late toxicity in the series was 
as follows: mastitis (6 cases, 15%), hypochromic skin 
spots at the catheter entrance and exit points (8 patients, 
20%), telangiectasia (7 patients, 17.5%), and fat necrosis 
(one case). Cosmetic outcomes determined according to 
on the 4-point Harvard breast cosmesis scale [25] were as 
follows: good (n = 23, 57.5%), fair (n = 6, 15%), and poor 
(n = 7, 17.5%); in 4 cases, no data were available (10%). 
Acute and late toxicity outcomes are shown in Table 4. 
Unfortunately, we do not have any data on cosmetic out-
comes after primary treatment. 
Discussion 
The present retrospective study describes surviv-
al and treatment-related toxicity outcomes in a series 
of 40 patients who underwent tumorectomy followed 
by either intraoperative or post-operative multicatheter 
brachytherapy as a salvage treatment for IBTR. Our find-
ings show that survival outcomes using this technique are 
good, with OS and CSS rates at 5 years of 85.3% and 96%, 
respectively. Importantly, only two patients in this series 
died of cancer-related causes, and only one developed lo-
cal relapse and bone metastasis. In the last 30 years, sev-
eral studies have been performed to validate the use of 
a second BCT in patients with IBTR. While mastectomy is 
still widely used for salvage treatment, there is a growing 
trend towards breast-conserving approaches consisting 
of tumorectomy plus re-irradiation (particularly APBI). 
The available data suggest that this approach is a valid al-
ternative to mastectomy [26,27,28]. Although no non-in-
feriority phase III studies are currently available, there is 
a growing body of evidence indicating that re-treatment 
with breast conserving procedures is both safe and effec-
tive, with excellent local control, survival, cosmesis, and 
patient’s satisfaction [26,27,28]. 
One of the main concerns in patients with IBTR is the 
risk of developing metastatic disease. The degree of risk 
appears to be associated with tumor-related prognostic 
factors and with the time elapsed between diagnosis of 
the original breast cancer and disease recurrence, which 
is considered an independent prognostic factor. Previous 
hormonotherapy or chemotherapy are also associated 
with the risk of developing systemic disease [3,29]. Inter-
Table 3. Treatment characteristics and dosimetric 
analysis 
Parameter
Doses and fractionation 
34 Gy/10 Fr n = 20 (50%) 
32 Gy/8 Fr n = 19 (47.5%) 
16 Gy in single fraction n = 1 (2.5%) 
Number of catheter plans 
Median 3 
Range 1-4 
Number of catheters 
Median 14 
Range 7-18 
Mean volume (cm3)
V100 115 
V150 38.5 
Median volume (cm3)
V100 132.5 
V150 37 
Minimum volume (cm3)
V100 54.8 
V150 16.4 
Maximum volume (cm3)
V100 164 
V150 65.2 
PTV volume (cm3)
Mean 115 
Range 93-137
Coverage index (CI) (%)
Mean 90.1 
Median 92.25 
Range 78.61-99
Dose non-uniformity ratio (DNR)
Mean 0.28 
Median 0.27 
Range 0.16-0.40 
estingly, the overall risk of developing distant metasta-
ses is approximately 30%, even in patients who undergo 
mastectomy or mastectomy plus re-irradiation. Overall 
survival rates range from 31% to 80% [2,30,31,32,33]. 
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Table 4. Acute and late toxicity profile 
n (%)
Acute toxicity 
Infectious mastitis 7 (17.5)
Hematoma 1 (2.5) 
Late toxicity 
Fibrosis G0-G2 26 (65)
Fibrosis G3 11 (27.5) 
Fibrosis G4 3 (7.5) 
Mastitis 6 (15) 
Hypochromic skin spots 8 (20) 
Skin hyperpigmentation 5 (12.5) 
Telangiectasia 7 (17.5) 
Fat necrosis 1 (2.5) 
In our series, three patients developed a second re-
lapse after salvage treatment. Published reports indicate 
that anywhere from 0% to 26% of patients will develop 
a second local recurrence after BCS with re-irradiation, 
with a 5-year disease-free survival (DFS) rate of approx-
imately 60% (range, 31% to 85%). Voogd et al. [30] ret-
rospectively evaluated 266 patients with IBRT treated 
by mastectomy alone and finding that 25% of patients 
developed a second local recurrence. In our series, the 
5-year local control was higher than 95%. The results re-
ported in the study conducted by the GEC-ESTRO Breast 
Cancer Working Group suggest that BCT with intersti-
tial brachytherapy is feasible and effective in preventing 
second local recurrences, and that this approach achieves 
OS, DFS, and local recurrence rates that are at least equiv-
alent to those obtained with salvage mastectomy. 
In our series, we inserted a median of 14 catheters, 
with an average PTV volume of 115 cc. We used large 
PTV volumes to ensure better coverage of the tumor bed, 
in accordance with the report by Hannoun-Levi et al. [8] 
who found that the second local recurrence rate was low-
er in patients who received higher delivered doses with 
a larger irradiated volume. 
Cosmesis 
Cosmetic outcomes and fibrosis were slightly worse 
in our series compared to other reports. However, these 
bad cosmesis results can be explained by the fact that our 
patients were treated for recurrent disease, which means 
they had already undergone two surgeries plus adjuvant 
external WBI. Although cosmesis was considered satis-
factory in most of the patients, our results suggest that pa-
tients with locally-recurrent disease should be informed 
that cosmetic outcomes may be less than optimal with this 
technique. Nevertheless, patients – and clinicians – may 
consider this to be an acceptable trade-off given the good 
survival rates achieved with this treatment approach, es-
pecially since the only alternative is mastectomy (with or 
without reconstructive surgery). Although several cases 
of acute and chronic mastitis were observed in our series, 
these were successfully managed with supportive thera-
py without need for additional surgery.
Study strengths and limitations 
The main limitations of this study are the retrospec-
tive study design and the relatively small sample size. 
Another limitation is the lack of a homogenous treatment 
scheme, which was modified during the study period. 
Nonetheless, the EQD2 was equivalent. 
Conclusions 
The use of the APBI for primary breast cancer is 
well-established in clinical practice. In patients who de-
velop ipsilateral breast cancer recurrence, the available 
evidence shows that a second conservative treatment 
should be considered in well-selected patients. The data 
reported in this study support the feasibility and safety 
of APBI, with multicatheter interstitial brachytherapy 
as a salvage treatment. The body of evidence from this 
and other studies suggests that this breast-conserving 
treatment approach is a reasonable alternative to mastec-
tomy. In our series, local control, survival, and toxicity 
outcomes were good. Although cosmetic outcomes were 
less than fully satisfactory in some patients, the only al-
ternative that these patients have is mastectomy. Salvage 
brachytherapy after tumorectomy seems to be safe and 
effective. However, randomized trials are needed to com-
pare this approach to mastectomy. 
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